Division of Preventive Medicine, Department of Medicine; Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02215-1204, USA.
BMJ. 2010 Nov 4;341:c5702. doi: 10.1136/bmj.c5702.
To evaluate the effect of vitamin E supplementation on incident total, ischaemic, and haemorrhagic stroke.
Systematic review and meta-analysis of randomised, placebo controlled trials published until January 2010.
Electronic databases (Medline, Embase, Cochrane Central Register of Controlled Trials) and reference lists of trial reports. Selection criteria Randomised, placebo controlled trials with ≥1 year of follow-up investigating the effect of vitamin E on stroke. Review methods and data extraction Two investigators independently assessed eligibility of identified trials. Disagreements were resolved by consensus. Two different investigators independently extracted data. Risk ratios (and 95% confidence intervals) were calculated for each trial based on the number of cases and non-cases randomised to vitamin E or placebo. Pooled effect estimates were then calculated.
Nine trials investigating the effect of vitamin E on incident stroke were included, totalling 118 765 participants (59 357 randomised to vitamin E and 59 408 to placebo). Among those, seven trials reported data for total stroke and five trials each for haemorrhagic and ischaemic stroke. Vitamin E had no effect on the risk for total stroke (pooled relative risk 0.98 (95% confidence interval 0.91 to 1.05), P=0.53). In contrast, the risk for haemorrhagic stroke was increased (pooled relative risk 1.22 (1.00 to 1.48), P=0.045), while the risk of ischaemic stroke was reduced (pooled relative risk 0.90 (0.82 to 0.99), P=0.02). There was little evidence for heterogeneity among studies. Meta-regression did not identify blinding strategy, vitamin E dose, or morbidity status of participants as sources of heterogeneity. In terms of absolute risk, this translates into one additional haemorrhagic stroke for every 1250 individuals taking vitamin E, in contrast to one ischaemic stroke prevented per 476 individuals taking vitamin E.
In this meta-analysis, vitamin E increased the risk for haemorrhagic stroke by 22% and reduced the risk of ischaemic stroke by 10%. This differential risk pattern is obscured when looking at total stroke. Given the relatively small risk reduction of ischaemic stroke and the generally more severe outcome of haemorrhagic stroke, indiscriminate widespread use of vitamin E should be cautioned against.
评估维生素 E 补充剂对总卒中、缺血性卒中和出血性卒中的影响。
系统评价和对截至 2010 年 1 月发表的随机、安慰剂对照试验的荟萃分析。
电子数据库(Medline、Embase、Cochrane 中央对照试验注册)和试验报告的参考文献列表。
随机、安慰剂对照、随访时间≥1 年的试验,调查维生素 E 对卒中的影响。
两位研究者独立评估所确定试验的合格性。意见不一致时通过协商解决。两位不同的研究者独立提取数据。基于随机分配至维生素 E 或安慰剂的病例和非病例数量,为每个试验计算风险比(及 95%置信区间)。然后计算汇总的效应估计值。
纳入 9 项研究维生素 E 对卒中发病影响的试验,共计 118765 名参与者(59357 名随机分配至维生素 E 组,59408 名随机分配至安慰剂组)。其中,7 项试验报告了总卒中数据,5 项试验各报告了出血性卒中和缺血性卒中数据。维生素 E 对总卒中风险无影响(汇总相对风险 0.98(95%置信区间 0.91 至 1.05),P=0.53)。相反,出血性卒中风险增加(汇总相对风险 1.22(1.00 至 1.48),P=0.045),而缺血性卒中风险降低(汇总相对风险 0.90(0.82 至 0.99),P=0.02)。研究间几乎无异质性证据。元回归未发现盲法策略、维生素 E 剂量或参与者的发病状态是异质性的来源。就绝对风险而言,这意味着每 1250 名服用维生素 E 的人中就会增加 1 例出血性卒中,而每 476 名服用维生素 E 的人中就会预防 1 例缺血性卒中。
在这项荟萃分析中,维生素 E 使出血性卒中风险增加 22%,使缺血性卒中风险降低 10%。当观察总卒中时,这种不同的风险模式被掩盖了。鉴于缺血性卒中的风险降低相对较小,且出血性卒中的结局通常更为严重,应谨慎反对不加区分地广泛使用维生素 E。